Megan L Goodall

University Of Colorado Denver

$123,629

Attributed

$123,629

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $59.5K · FY2016–18

$100K$75K$50K$25K$0

'16

'17

'18

Funding mix

By agency

NIH$123,629 · 1

By mechanism

F32$123,629 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Anti-Cancer Therapeutic”

Leonard Freedman · Leidos Biomedical Research, Inc.$238,890,071
Gregory H Reaman · National Childhood Cancer Foundation$156,216,380
Peter J O'Dwyer · University Of Pennsylvania$94,003,288
Lynn Briscoe · Leidos Biomedical Research, Inc.$72,762,362
Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
Douglas S. Hawkins · Children'S Hosp Of Philadelphia$50,338,647

Research focus

Anti-Cancer TherapeuticAntitumor AgentApoptosisAutophagocytosisBaseCancer DiagnosisCancer EtiologyCancer InitiationCancer TherapyCdh1 GeneCell DeathCell PhysiologyCellsCell SurvivalCessation Of LifeChd1 GeneChemical ModifierChloroquineClinically RelevantComplexConfocal MicroscopyDesignDisease-Free SurvivalAffect

Grant awards (4)

Investigating the role of autophagy in Tak1 null prostate cancer and TRAIL sensitivity$8,029

F32 · FY2018 · CA · contact PI

Investigating the role of autophagy in Tak1 null prostate cancer and TRAIL sensitivity$59,166

F32 · FY2017 · CA · contact PI

Investigating the role of autophagy in Tak1 null prostate cancer and TRAIL sensitivity$316

F32 · FY2017 · CA · contact PI

Investigating the role of autophagy in Tak1 null prostate cancer and TRAIL sensitivity$56,118

F32 · FY2016 · CA · contact PI